Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q1 2024 · 10-Q
Revenue$205.00K$205.00K+147.0% vs Q1 2023 Net Income-$10.01M-$10.01MN/M vs Q1 2023 EPS Diluted-$0.22-$0.22N/M vs Q1 2023 Operating Income-$10,933,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Free Cash Flowderived-$7,820,000N/M Margins · derivedOperating margin-5333.2%+9187.3 pt vs Q1 2023
Net margin-4883.4%+8638.3 pt vs Q1 2023
ended Mar 31, 2024 · filed May 2, 2024 · 32 d after period end